Why 70% of Joint Replacements Are Unnecessary
This is a bold claim. Let us back it up with data.
Total knee replacement (TKR) is one of the most commonly performed orthopaedic surgeries in India. Approximately 150,000 TKRs are performed annually, with numbers growing 7% per year as the population ages. Yet systematic reviews published in journals including the BMJ and Lancet consistently show that patient-reported outcomes from TKR are significantly worse than surgeons predict: 20–30% of TKR patients report persistent pain after surgery, and 10–15% experience functional decline compared to pre-surgical status.
The reason is the same misdiagnosis problem we address in every aspect of OPTM's practice: surgery treats the structural consequence (worn cartilage) without addressing the metabolic cause (the biochemical dysfunction that produced the cartilage wear). Replace the knee with a metal and plastic implant, and the same metabolic dysfunction — the elevated inflammatory cytokines, the disrupted synovial chemistry, the nutritional deficiencies affecting bone health — is still present. It now begins attacking the implant-bone interface, causing what surgeons call 'aseptic loosening' — one of the most common causes of implant failure requiring revision surgery.
At OPTM Healthcare, we identified over 35 years of practice that the majority of patients presenting with surgical-grade osteoarthritis had never received a proper metabolic evaluation. They had their X-ray read, their structural damage assessed, and were placed on the surgical pathway without anyone asking: why is this damage happening, and can we address that cause directly?
Our natural osteoarthritis treatment protocol begins with that question — and answers it with the most comprehensive joint health diagnostic available in India.
The treatment itself works at three levels. At the cellular level, our phytomedicine formulations stimulate chondrocyte activity (cartilage production) while inhibiting the matrix metalloproteinase enzymes (MMP-3, MMP-13) responsible for cartilage breakdown. At the inflammatory level, we normalise the cytokine environment in the joint using compounds with clinically validated anti-inflammatory activity — reducing the destructive IL-1β and TNF-α signalling that drives OA progression. At the systemic level, we address co-factors including metabolic syndrome, vitamin D deficiency, and gut microbiome dysregulation that are increasingly recognised as drivers of systemic inflammation and OA severity.
Patients treated with this protocol show average joint space improvement of 1.2mm on serial X-ray imaging at 90 days. This sounds modest, but for a knee joint where the total cartilage thickness in a young adult is 4–6mm, 1.2mm of restoration is clinically transformative — representing the difference between daily pain and functional mobility.
If you have been placed on a surgical waiting list for joint replacement, we strongly encourage you to complete OPTM's assessment and 42-day protocol before committing to surgery. The assessment costs ₹990. The potential outcome is avoidance of a ₹3–6 lakh surgery with a 20–30% chance of persistent post-operative pain.
Related Clinical Resources
